New findings show women with early stage breast cancer can avoid chemotherapy. Researchers now say most women with smaller tumors can safely skip the treatment and avoid side effects like fatigue and nausea. Amna Nawaz learns more from Dr. Larry…
Endometrial cancer, a common form of uterine cancer, has an 80 percent rate of survival over a five-year period in most women diagnosed at age 60 and above. But African American women are more likely to have a more aggressive…
By Dr. Amber Robins
The race to create the next potent ovarian cancer drug is coming to a head.
By Meghana Keshavan, STAT
33 percent of patients with HIV and lung cancer failed to receive any treatment for the cancer compared with 14 percent of those who weren’t infected.
By Michelle Andrews, Kaiser Health News
By Julie Appleby, Kaiser Health News
Some cancer patients and their insurers are seeing their bills for chemotherapy jump sharply, reflecting increased drug prices and hospitals’ push to buy oncologists’ practices and then bill at higher rates.
By Jason Kane
No sushi. No caffeine. No alcohol. No Ibuprofin. Minnie Narth could recite everything she'd heard she wasn't supposed to have while pregnant. But as she entered her third trimester, her body was in desperate need of something she would never…
By Jason Kane
It was President Nixon's "Christmas gift to the nation." On Dec. 23, 1971, he faced the television cameras in the East Room of the White House and declared "total national commitment" to finding a cure for cancer and the funds…
As a part of NewsHour Connect, which showcases some of the best public broadcasting reporting from around the country, Enrique Cerna of KCTS in Seattle reports on the dangers that chemotherapy drugs could pose to healthcare workers who handle them.
Researchers reported new progress in the treatment of breast, skin, lung and ovarian cancers at a weekend meeting of top cancer experts in Chicago. Ray Suarez talks to American Society of Clinical Oncology President George Sledge for an update on…
Support Provided By: Learn more
Educate your inbox
Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.